Spectrum Wealth Advisory Group’s Madrigal Pharmaceuticals MDGL Stock Holding History

Spectrum Wealth Advisory Group’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.15K	Buy	+4	New	+$2.05K	﹤0.01%	330

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Spectrum Wealth Advisory Group's MDGL Position: Q2 2026 in Review

Spectrum Wealth Advisory Group opened a new position in Madrigal Pharmaceuticals (MDGL) in Q2 2026: 4 shares worth $2.15K. The stake represents ﹤0.01% of the portfolio and ranks #330 among its holdings.

413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Spectrum Wealth Advisory Group held 4 shares of Madrigal Pharmaceuticals worth $2.15K as of Q2 2026.
Madrigal Pharmaceuticals was a new Spectrum Wealth Advisory Group position in Q2 2026.
Madrigal Pharmaceuticals made up ﹤0.01% of Spectrum Wealth Advisory Group's portfolio in Q2 2026, its #330 holding.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Spectrum Wealth Advisory Group's 13F filing for Q2 2026, filed 6 Aug 2026.